151 related articles for article (PubMed ID: 1934249)
1. Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Cancer Chemother Pharmacol; 1991; 28(6):455-60. PubMed ID: 1934249
[TBL] [Abstract][Full Text] [Related]
2. [Ifosfamide and the metabolites of side chain oxidation--excretion in urine in various pediatric therapeutic protocols].
Boos J; Welslau U; Ritter J; Blaschke G; Schellong G
Klin Padiatr; 1992; 204(4):299-305. PubMed ID: 1518269
[TBL] [Abstract][Full Text] [Related]
3. Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
Silies H; Blaschke G; Hohenlöchter B; Rossi R; Jürgens H; Boos J
Int J Clin Pharmacol Ther; 1998 May; 36(5):246-52. PubMed ID: 9629987
[TBL] [Abstract][Full Text] [Related]
4. Ifosfamide enantiomers: pharmacokinetics in children.
Prasad VK; Corlett SA; Abaasi K; Heney D; Lewis I; Chrystyn H
Cancer Chemother Pharmacol; 1994; 34(5):447-9. PubMed ID: 8070015
[TBL] [Abstract][Full Text] [Related]
5. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
6. Trofosfamide metabolism in different species--ifosfamide is the predominant metabolite.
Boos J; Küpker F; Blaschke G; Jürgens H
Cancer Chemother Pharmacol; 1993; 33(1):71-6. PubMed ID: 8269592
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
Cerny T; Graf A; Rohner P; Zeugin T; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S129-34. PubMed ID: 1795001
[TBL] [Abstract][Full Text] [Related]
8. Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1996; 38(2):147-54. PubMed ID: 8616905
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
Willits I; Price L; Parry A; Tilby MJ; Ford D; Cholerton S; Pearson AD; Boddy AV
Br J Cancer; 2005 May; 92(9):1626-35. PubMed ID: 15827549
[TBL] [Abstract][Full Text] [Related]
10. Comparison of continuous infusion and bolus administration of ifosfamide in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Eur J Cancer; 1995; 31A(5):785-90. PubMed ID: 7640054
[TBL] [Abstract][Full Text] [Related]
11. Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics.
Boddy AV; English M; Pearson AD; Idle JR; Skinner R
Eur J Cancer; 1996 Jun; 32A(7):1179-84. PubMed ID: 8758250
[TBL] [Abstract][Full Text] [Related]
12. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
[TBL] [Abstract][Full Text] [Related]
13. Stereoselective metabolism of ifosfamide by human P-450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer.
Roy P; Tretyakov O; Wright J; Waxman DJ
Drug Metab Dispos; 1999 Nov; 27(11):1309-18. PubMed ID: 10534317
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1993; 33(1):36-42. PubMed ID: 8269587
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, metabolism and clinical effect of ifosfamide in breast cancer patients.
Boddy AV; Proctor M; Simmonds D; Lind MJ; Idle JR
Eur J Cancer; 1995; 31A(1):69-76. PubMed ID: 7695982
[TBL] [Abstract][Full Text] [Related]
16. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
Patzer L; Hernando N; Ziegler U; Beck-Schimmer B; Biber J; Murer H
Kidney Int; 2006 Nov; 70(10):1725-34. PubMed ID: 17003823
[TBL] [Abstract][Full Text] [Related]
17. Carnitine deficiency and oxidative stress provoke cardiotoxicity in an ifosfamide-induced Fanconi Syndrome rat model.
Sayed-Ahmed MM; Darweesh AQ; Fatani AJ
Oxid Med Cell Longev; 2010; 3(4):266-74. PubMed ID: 20972373
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the urinary excretion of ifosfamide and its N-dechloroethylated metabolites in children using 31P-NMR spectroscopy.
Misiura K; Zubowska M; Zielińska E
Arzneimittelforschung; 2003; 53(5):372-7. PubMed ID: 12854365
[TBL] [Abstract][Full Text] [Related]
19. Poly-isoprenylated ifosfamide analogs: Preactivated antitumor agents as free formulation or nanoassemblies.
Skarbek C; Delahousse J; Pioche-Durieu C; Baconnais S; Deroussent A; Renevret P; Rivard M; Desmaele D; Martens T; Le Cam E; Couvreur P; Paci A
Int J Pharm; 2017 Nov; 532(2):748-756. PubMed ID: 28546071
[TBL] [Abstract][Full Text] [Related]
20. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
